North China Pharmaceutical to Raise R & D Ability      

North China Pharmaceutical Company Ltd. (North China pharmaceutical SH: 600812), based in Shijiazhuang of Hebei province, announced on January 9th it intends to acquire a 77.84% interest in NCPC New Drug R & D Co., Ltd. from North China Pharmaceutical Group Corporation (NCPC) , to strengthen its new drug R & D ability.
   NCPC R & D, founded in 1957, has become a leading pharmaceutical R & D enterprise in China, especially in microbial fermentations and organic synthesis. It engages in R & D, manufacture and sales of high quality active pharmaceutical ingredients (APIs) and new generic finished pharmaceutical products. As of the end of 2008, the equity split in NCPC New Drug R & D is 77.84: 20.09: 2.07 between NCPC, North China Pharmaceutical and Yunnan Institute of Microbiology.  
    North China Pharmaceutical hopes to advance its R & D capacity of new pharmaceuticals through the acquisition and raise its profit-making ability as well as consolidate its leading position in pharmaceutical manufacturer in China now.